| ￥4100 | |
| Z05339-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 13.36 kDa | ||||
| Apparent Molecular Weight | The protein migrates to 15-16 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in 50mM HAc (pH 2.9). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM HAc (pH 2.9). | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized GDF15 (H202D), His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Human GFRAL, hFc Tag with the EC50 of 15.3 ng/ml determined by ELISA. »
GDF15 (H202D), His, Human on Bis-Tris PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%. »
| Target Background | Growth Differentiation Factor 15 (GDF15), also known as NSAID activated gene-1 (NAG-1), is associated with a large number of biological processes and diseases, including cancer and obesity. GDF15 is synthesized as pro-GDF15, is dimerized, and is cleaved and secreted into the circulation as a mature dimer GDF15. |
| Synonyms | GDF-15; MIC-1; NAG-1; PDF; PLAB; PTGFB; GDF15; MIC1; RG-1; Placental TGF-beta; PTGF-beta; PTGFBPTGF-beta; Placental TGF-β; PTGF-β; PTGFBPTGF-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
